search returned 100 results for adalimumab, showing results 61 to 70
/PBS Lising changes for rheumatology medicines
Adalimumab for vision threatening non-infectious uveitis
Adalimumab for enthesitis / spondylitis related juvenile arthritis
Anifrolumab for SLE
https://rheumatology.org.au/LinkClick.aspx?fileticket=MSJ026abHmM%3d&portalid=2
are to be applied to all formulations
of adalimumab, certolizumab pegol, etanercept, golimumab, infliximab... active
rheumatoid arthritis, and all formulations of adalimumab and etanercept listed
https://rheumatology.org.au/LinkClick.aspx?fileticket=kFKDqhqev0A%3d&portalid=2
relationship
• PBAC working group
• Expanded adalimumab access for juvenile arthritis
https://rheumatology.org.au/LinkClick.aspx?fileticket=7fVNd8KekI0%3d
list reviewed; all items completed except– Pharmacy issues re:
adalimumab biosimilars and supply... this issue. Adalimumab ongoing, waiting for a response from DoH. If you
experience any issues with e... and allocated them
amongst the TC members.
o MM allocated adalimumab, certolizumab, etanercept
https://rheumatology.org.au/LinkClick.aspx?fileticket=dnhVlc%2fS5iM%3d
relationship
• PBAC working group
• Expanded adalimumab access for juvenile arthritis
https://rheumatology.org.au/LinkClick.aspx?fileticket=7fVNd8KekI0%3d&portalid=2
list reviewed; all items completed except– Pharmacy issues re:
adalimumab biosimilars and supply... this issue. Adalimumab ongoing, waiting for a response from DoH. If you
experience any issues with e... and allocated them
amongst the TC members.
o MM allocated adalimumab, certolizumab, etanercept
https://rheumatology.org.au/LinkClick.aspx?fileticket=dnhVlc_S5iM%3d&portalid=2
was
undertaken prior to the widespread availability of adalimumab biosimilars and
encourage any future... adalimumab listing as a HSD not general schedule listing
5. The APRG estimate that patients who receive adalimumab or etanercept on compassionate
grounds for non-PBS indications (uveitis or SaJIA not covered
https://rheumatology.org.au/LinkClick.aspx?fileticket=VaOIA0IuXwg%3d
was
undertaken prior to the widespread availability of adalimumab biosimilars and
encourage any future... adalimumab listing as a HSD not general schedule listing
5. The APRG estimate that patients who receive adalimumab or etanercept on compassionate
grounds for non-PBS indications (uveitis or SaJIA not covered
https://rheumatology.org.au/LinkClick.aspx?fileticket=VaOIA0IuXwg%3d&portalid=2
re:
adalimumab biosimilars and supply of Humira as still pending response from
Pharmaceutical... and anifrolumab)
7.6 PBAC Meeting November agenda (adalimumab)
• The PBAC have released the Nov meeting agenda and the TC are invited to comment.
AbbVie have put in request for adalimumab and upadacitinib
https://rheumatology.org.au/LinkClick.aspx?fileticket=mw14abImwDM%3d
re:
adalimumab biosimilars and supply of Humira as still pending response from
Pharmaceutical... and anifrolumab)
7.6 PBAC Meeting November agenda (adalimumab)
• The PBAC have released the Nov meeting agenda and the TC are invited to comment.
AbbVie have put in request for adalimumab and upadacitinib
https://rheumatology.org.au/LinkClick.aspx?fileticket=mw14abImwDM%3d&portalid=2